Open-Label, Randomized, Controlled Phase I/II Study of Cilengitide to Evaluate the Safety and Efficacy of the Combination of Different Regimens of Cilengitide Added to Cisplatin, 5-FU, and Cetuximab in Subjects With Recurrent/Metastatic Squamous Cell Cancer of the Head and Neck.

Trial Profile

Open-Label, Randomized, Controlled Phase I/II Study of Cilengitide to Evaluate the Safety and Efficacy of the Combination of Different Regimens of Cilengitide Added to Cisplatin, 5-FU, and Cetuximab in Subjects With Recurrent/Metastatic Squamous Cell Cancer of the Head and Neck.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 10 Sep 2016

At a glance

  • Drugs Cilengitide (Primary) ; Cetuximab; Cisplatin; Fluorouracil
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Acronyms ADVANTAGE
  • Sponsors Merck KGaA
  • Most Recent Events

    • 28 Mar 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 10 Oct 2012 Planned end date changed from 1 Nov 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 05 Jun 2012 Phase II results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top